Smaller Loss Persists Across Both Windows in Milestone Scientific Interim Filing

Bottom line

- The bottom line remained negative on both reporting windows in the filing, with the loss narrower than the prior-year loss on a per-share basis; earnings per share moved in the authorized "increase" direction (still a loss) on the three-month period versus the prior-year three-month period, and the same direction applies to the six-month year-to-date period versus the prior-year six-month period. - Net Income (Loss) Attributable to Parent likewise followed the authorized "increase" direction (loss to loss, narrower) on both the quarter and the year-to-date window when each is compared with the prior-year period, mirroring the EPS movement.

- Operating Income (Loss) also moved in the authorized "increase" direction (loss to loss, narrower) on both windows, consistent with the direction registered for net result and EPS; the operating line therefore supports the headline conclusion that the company remains in operating loss territory even after the favorable year-over-year movement. - All three reported dimensions — diluted EPS, net result, and operating result — agree on direction and on the loss-to-loss transition, with no metric in this section's catalog showing a swing to profit.

- Reporting-period identity: this analysis covers the 10-Q filed by MILESTONE SCIENTIFIC INC. ([ticker: MLSS], CIK 0000855683) for the fiscal period period-ended-2026-06-30, filed under accession 0001493152-26-037761; the three-month reporting period is referenced as the three months ended June 30, 2026 with its prior-year counterpart the three months ended June 30, 2025, and the six-month year-to-date period as the six months ended June 30, 2026 with prior-year counterpart the six months ended June 30, 2025. - Source scope: figures drawn from the income-statement summary lines listed in the section's catalog; supporting context also reviewed the Part II items visible in the filing — including the Legal Proceedings and Risk Factors discussion under Item 1 and Item 1A, the Unregistered Sales of Equity item under Item 2, the Quantitative and Qualitative Disclosures About Market Risk and Controls and Procedures items under Item 3 and Item 4, and the forward-looking statements block under Item 5 and Item 6 — for orientation only, not as a source of period values.

- The filing evidence does not attribute this change to any single cause. The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison.

The filing evidence contains no peer or industry comparison. - Within this section, every reported dimension — diluted EPS, net result, and operating result — is grounded in the catalog and is therefore considered known; period-level details such as revenue, cost of revenue, and cash-flow lines, and any segment split, are outside this section's scope and are intentionally left to subsequent sections rather than narrated here. - Readers looking to sanity-check the qualitative direction of the loss-narrowing call against a simple rate-of-return framing can use the ROI Calculator without relying on it as a substitute for the filing figures.

Financial performance

- For the three-month reporting period of period-ended-2026-06-30, Milestone Scientific Inc. (MLSS, 0000855683) reported a net loss attributable to the parent of -$1,059,332 USD, versus a net loss of -$1,483,110 USD in the prior-year three-month comparative. 02 per diluted share USD per share a year earlier.

Operating result was an operating loss of -$1,061,563 USD for the quarter, compared with an operating loss of -$1,484,631 USD in the prior-year three-month window. - For the six-month year-to-date period, the net loss attributable to the parent was -$1,899,185 USD, against a net loss of -$3,477,696 USD for the prior-year six-month comparative. 04 per diluted share USD per share a year earlier.

Operating result was an operating loss of -$1,889,645 USD for the half-year period, compared with an operating loss of -$3,482,484 USD in the prior-year six-month comparative. - The authorized year-over-year comparisons indicate that net loss attributable to the parent narrowed on both the three-month and six-month bases relative to the prior year (a smaller loss in each window); diluted earnings per share also moved higher (a smaller per-share loss) on both reporting windows; and operating loss was shallower on both reporting windows than in the prior year.

No transition from profit to loss, or loss to profit, occurred — the result was a loss in every reported period. - The filing does not present quarter-versus-prior-quarter sequential comparisons in the cited evidence, so no quarter-over-quarter movement can be asserted for these dimensions. The filing evidence does not attribute this change to any single cause.

- Forward-looking statements appear under the standard heading near Item 6, where management reiterates the cautionary language and undertakes no obligation to revise or update such statements except as required by federal securities laws. The filing does not provide quantitative guidance (no revenue, EPS, operating loss, or cash runway targets) for the next quarter or the full year. - The going-concern note accompanying the condensed consolidated financial statements discloses that the Company has incurred total losses since inception and reported operating losses for the three- and six-month periods covered, with the April private placement described as having improved the liquidity position.

The filing evidence does not attribute this change to any single cause. is the only causality statement supported by the cited evidence. S.

GAAP for interim financial information per the instructions to 10-Q and the relevant article of Regulation S-X, with management representing that normal recurring adjustments are necessary for a fair presentation of the the three months ended June 30, 2026 and the six months ended June 30, 2026 results. - Reader-facing analytical takeaway: the headline profitability measures (net loss, diluted EPS, operating loss) all moved in the same direction — smaller losses — on a year-over-year basis for both the three-month and six-month windows of period-ended-2026-06-30.

No peer or industry benchmark is included in the filing. The filing evidence contains no peer or industry comparison. No segment-level breakdown is disclosed for these dimensions.

The filing evidence does not disclose segment-level detail for this dimension. - For readers comparing interim results, the ROI Calculator can frame the wider earnings context but cannot substitute for the filed figures; the underlying profitability comparisons above are the only quantified outcomes in this section.

Operating drivers and segments

- Milestone Scientific reports operating results only on a consolidated basis across the two reporting windows tracked in this filing, so segment-level revenue, segment-level cost of sales, or segment-level operating performance is not separately disclosed for either the three-month period the three months ended June 30, 2026 or the six-month year-to-date period the six months ended June 30, 2026. - Operating Income (Loss) was -$1,061,563 for the three months ended June 30, 2026 and -$1,889,645 for the six months ended June 30, 2026, in each case a loss rather than a profit. The authorized direction for Operating Income (Loss) between the prior period and the current period is increase on both windows, with the current period and the prior-year comparative both being a loss; the transition is loss to loss. - Prior-year comparative Operating Income (Loss) was -$1,484,631 for the three months ended June 30, 2025 and -$3,482,484 for the six months ended June 30, 2025, both negative, which means the year-over-year improvement still leaves the company below break-even on operations. - Gross margin, operating expense mix, and contribution by product line versus geographic mix are not provided at the level needed to attribute the change between the current and prior-year Operating Income (Loss) figures; the filing presents only the consolidated Operating Income (Loss) line.

- Management frames the forward-looking commentary through the safe-harbor language repeated in the 10-Q cover, covering forward-looking statements within the meaning of the cited Exchange Act sections and the Private Securities Litigation Reform Act of the cited year, as set out in the Item 6 signatures/forward-looking statements section and mirrored earlier in the Item 5 block. - The only operational driver explicitly named in the cited narrative is the planned continued expansion of the business, with management noting that any assumptions underlying the forward-looking statements could prove inaccurate. - The recently issued Accounting Standards Update from the Financial Accounting Standards Board in November of the cited year is acknowledged as a future disclosure requirement covering employee compensation, depreciation, and intangible asset amortization disaggregation; the filing presents this as a forthcoming reporting change rather than as a current period driver of operating results. - Management does not, within the cited text, attribute the change in Operating Income (Loss) between the three months ended June 30, 2025 and the three months ended June 30, 2026 or between the six months ended June 30, 2025 and the six months ended June 30, 2026 to any specific revenue, cost, or volume driver.

The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison.

Readers comparing Milestone Scientific's interim operating performance against broader medical-device or dental-instrument peers can size the consolidated operating-loss change with the ROI Calculator before drawing conclusions about capital efficiency, given that no segment cuts are disclosed and no peer benchmark is contained in the filing evidence.

Cash flow and capital

- Reported facts — Operating, investing, and financing cash flow lines are each presented for both the current six-month year-to-date period and its prior-year comparative. Operating cash flow was negative in both windows, with the current period's outflow of -$498,285 narrower than the prior-year comparative of -$2,772,273. Investing cash flow was also negative in both windows, with the current period's outflow of -$5,771 deeper than the prior-year comparative of -$5,776.

Financing cash flow was positive in both windows, with the current period's inflow of $1,458,184 higher than the prior-year comparative of $794,305. Capital expenditures, captured as Payments to Acquire Property, Plant, and Equipment, were positive in both windows, with the current period's outlay of $5,771 lower than the prior-year comparative of $5,776. , citing cumulative losses since inception, operating losses for the three- and six-month periods, recurring losses, negative cash flows, and an accumulated deficit.

Management notes that completion of a private placement in April has improved the liquidity position, but adds that continuation as a going concern depends on generating sufficient revenue, managing operating expenses, and, if necessary, obtaining additional financing. - Analyst inference — The combination of a narrower operating outflow, a heavier investing outflow, and a heavier financing inflow versus the prior year is consistent with management drawing on fresh capital to fund a higher level of investment activity.

The reduction in capital expenditures year over year sits inside a heavier overall investing outflow, suggesting that the step-up in investing cash use is not driven by property, plant, and equipment additions alone. - Counter-evidence — None. The going concern paragraph itself acknowledges that capital from the April private placement has already improved liquidity, which sits against the wider investing outflow and the still-negative operating line; readers should weigh both signals.

The filing evidence contains no peer or industry comparison. - Unknowns — The filing evidence does not attribute this change to any single cause.

Peer and historical context

The filing under 10-Q for period-ended-2026-06-30 from MILESTONE SCIENTIFIC INC. (MLSS, CIK 0000855683, accession 0001493152-26-037761) supplies prior-year comparatives for both reporting windows but no peer or industry benchmark, so any cross-issuer read has to be framed against the company's own historical print rather than a sector cohort.

On the three-month window, the company remained in a loss position on both the top-of-operating and bottom lines. Operating Income (Loss) for the three months ended June 30, 2026 came in at -$1,061,563 USD, against -$1,484,631 USD in the three months ended June 30, 2025, with the authorized direction describing the change. Net Income (Loss) Attributable to Parent for the same window was -$1,059,332 USD versus -$1,483,110 USD, again in a loss-to-loss transition. Because diluted earnings per share were a loss in both the current and prior three-month periods, any per-share narrowing or widening is the relevant lens here rather than a swing to profit.

On the six-month year-to-date window, the loss profile is consistent with the quarterly read. Operating Income (Loss) for the six months ended June 30, 2026 was -$1,889,645 USD compared with -$3,482,484 USD for the six months ended June 30, 2025, again in a loss-to-loss transition under the authorized direction. Net Income (Loss) Attributable to Parent for the six-month period was -$1,899,185 USD against -$3,477,696 USD, with the same loss-to-loss framing. Diluted EPS, where disclosed, tracks that pattern: a loss in both the six months ended June 30, 2026 and the six months ended June 30, 2025, with the authorized direction describing the movement.

The cash-flow comparison tells a different and softer story. Net Cash Provided by (Used in) Operating Activities was -$498,285 USD for the six months ended June 30, 2026, versus -$2,772,273 USD for the six months ended June 30, 2025, both negative under the authorized direction. By contrast, Net Cash Provided by (Used in) Financing Activities and Net Cash Provided by (Used in) Investing Activities, both for the six-month window, moved in opposite directions to operating cash flow (financing positive in both years, investing negative in both years) per the authorized direction, and Payments to Acquire Property, Plant, and Equipment is authorized as a decrease on a year-over-year basis. That is the only place in this section where the underlying base shifts from a loss to a different sign — but it is a financing or capex lens, not an earnings one.

There is no authorized comparison in the catalog for revenue, gross margin, cost of revenue, share count, or any segment line for this issuer, so any commentary on those dimensions is intentionally omitted here. The reader-facing takeaway is narrower than a typical earnings narrative: the year-over-year record here is one of a loss persisting on both the quarter and the half-year, with operating cash outflows continuing and a capital-allocation pattern that the authorized direction marks as moving in the opposite direction from operating cash flow.

The filing evidence does not attribute this change to any single cause.

The filing evidence contains no peer or industry comparison.

Scenario analysis

- The base case for MILESTONE SCIENTIFIC INC. (MLSS) under 10-Q for period-ended-2026-06-30 reflects the reported reality on the income line, where -$1,899,185 remained a loss attributable to the parent for the six months ended June 30, 2026, while the prior-year comparable -$3,477,696 for the six months ended June 30, 2025 was also a loss; the only direction the catalog authorizes is an increase in the loss-to-loss transition, meaning the current half-year loss is deeper than the prior-year loss. The filing evidence does not attribute this change to any single cause.

- The same loss-to-loss pattern shows up in the three-month window, with -$1,059,332 for the three months ended June 30, 2026 running at a loss attributable to the parent and the prior-year comparative -$1,483,110 for the three months ended June 30, 2025 also a loss; the authorized direction is an increase in that loss, leaving the quarter in a deeper-loss posture than the year-ago period. The filing evidence does not attribute this change to any single cause. - Operating Income Loss behaves consistently on the authorized axes: for the six months ended June 30, 2026 compared with the six months ended June 30, 2025 the period moved from a loss to a loss with an authorized increase in the loss, and for the three months ended June 30, 2026 compared with the three months ended June 30, 2025 the same loss-to-loss transition with an authorized increase in the loss applies, so the upside case hinges on whether operating drag can stabilize rather than continue to deepen.

The filing evidence does not attribute this change to any single cause. - The diluted EPS authorized comparisons reinforce this read: for the six months ended June 30, 2026 versus the six months ended June 30, 2025 the metric moves from a loss to a loss with an authorized increase in the loss, and for the three months ended June 30, 2026 versus the three months ended June 30, 2025 the loss-to-loss transition again carries an authorized increase in the loss, framing the base scenario around wider per-share losses on both reporting windows.

The filing evidence does not attribute this change to any single cause. - The upside case sits on the cash-flow side, where the authorized directions show improvement rather than deterioration: for the six months ended June 30, 2026 versus the six months ended June 30, 2025, Net Cash Provided by Used in Financing Activities is authorized to increase from a positive prior-year figure, while Net Cash Provided by Used in Investing Activities moves higher while remaining negative and Payments to Acquire Property Plant and Equipment is authorized to decrease, pointing to a softer capex footprint alongside continued financing inflows.

Net Cash Provided by Used in Operating Activities is authorized to increase while remaining negative, so the operating burn narrows rather than reverses. - The downside case reflects the dilution overhang called out in the source narrative, where potentially dilutive outstanding stock options, unissued restricted stock awards, unconverted convertible notes, and warrants were excluded from the diluted EPS calculation for the three and six months covered by this filing because their effect would be anti-dilutive against the reported losses; together with the warrant Purchase Agreement referenced in the cited stockholders' equity note, this overhang frames a scenario in which any future swing toward profitability would mechanically re-introduce dilutive instruments into the share count.

- Management addresses the dilution topic only in the accounting-policy sense, noting the assessment of warrant classification under the relevant authoritative guidance, while forward-looking context appears in the cited forward-looking statements section under Item 6 and risk context under Item 1A, with no management projection of revenue, pricing, or margin recovery in the filing evidence. The filing evidence contains no peer or industry comparison. - The downside reading is also bounded by the absence of any peer or industry comparison in the filing, so a relative underperformance versus comparable medical-device issuers cannot be drawn from the cited materials; readers evaluating MLSS against peers must look outside 0001493152-26-037761.

The filing evidence contains no peer or industry comparison. - Within those limits, readers modelling a recovery path can frame expectations of return on incremental capital using an ROI Calculator, since the authorized directions on capex and operating burn give the inputs most likely to feed such an exercise for the six months ended June 30, 2026 relative to the six months ended June 30, 2025.

Risks and what to watch

The MILESTONE SCIENTIFIC INC. filing under 10-Q for period-ended-2026-06-30 (0001493152-26-037761) sits in a loss position across both reporting windows, and the net-income line is the clearest single-screen summary of the risk posture. Net Income (Loss) Attributable to Parent was -$1,899,185 for the six months ended June 30, 2026 and -$1,059,332 for the three months ended June 30, 2026, compared with -$3,477,696 for the six months ended June 30, 2025 and -$1,483,110 for the three months ended June 30, 2025. Both periods remain in a loss, but the headline figure moved in the direction of a smaller loss, which is the only direction we are authorized to assert — the cause of the move is not something the reader can pin to a single driver from this evidence, so the right word here is The filing evidence does not attribute this change to any single cause..

Counter-evidence for any "improvement" narrative is also thin. The filing does not break out segment-level detail for the dental versus medical instrument lines, so we cannot tell whether the year-to-date change is driven by Single Tooth Anesthesia System® (STA) instrument shipments, by the epidural instrument and replacement-parts business, or by a swing in operating expense timing — see The filing evidence does not disclose segment-level detail for this dimension.. The filing evidence contains no peer or industry comparison, so any claim that the smaller loss is "better than the sector" is unsupported: The filing evidence contains no peer or industry comparison. is the only honest framing. The filing also permits warrants to be classified as liabilities and remeasured at fair value each reporting period, which means a non-cash mark-to-market swing could move the bottom line independently of operations; the warrant assessment language in the stockholders' equity note is the lever to watch, and readers should size runway risk with ROI Calculator when thinking about dilution scenarios.

Unknowns worth flagging for the next period: - Whether the smaller loss shown in the three months ended June 30, 2026 continues to compress into the next reporting window, or whether quarter-specific expense timing distorted the comparison. - The size and classification of any new warrant issuance or modification, given the equity-versus-liability trigger language in the warrant note under Item 1. - Whether the advances-on-contracts balance — funding tied to future STA devices, epidural instruments, and epidural replacement parts — converts into revenue on the expected timeline, or whether it sits longer as a current asset. - Allowance movements: the disclosed decrease was attributed to the disposal of fully reserved inventory, with the filing calling the impact immaterial, so an unchanged reserve policy is the base assumption rather than a confirmed fact.

Metrics to watch next period, framed only in qualitative terms readers can verify in the next interim filing: - The direction and sign of Net Income (Loss) Attributable to Parent for the next three-month and year-to-date windows, versus the prior-year comparatives already cited. - Any change in the warrant liability balance disclosed under Item 1A, which can move earnings without an operating change. - Operating cash usage relative to financing inflows, which together frame the runway question. - The trajectory of the advances-on-contracts balance and the underlying instrument order book.

Forward-looking statements in Item 5 and Item 6 remind readers that any outlook language is qualified, and Item 4 / Item 3 confirm the controls and market-risk disclosures are repeated each period without new quantification here.